Diabetic Kidney Problems

Diabetes is the leading cause of chronic kidney disease in India and worldwide. About 30–40% of people with type 1 and 20–30% with type 2 diabetes eventually develop kidney disease — but good control and the right medicines can dramatically reduce that risk.

How it progresses

• Hyperfiltration (early) — eGFR may be higher than normal.
• Microalbuminuria (30–300 mg/g) — first detectable damage; still reversible.
• Overt proteinuria — bigger protein losses, rising creatinine.
• CKD — eGFR falls steadily; blood pressure rises.
• End-stage renal disease — dialysis or transplant.
• Often silent until advanced — which is why screening matters.

Screening — every year

• Urine albumin-to-creatinine ratio (uACR) and serum creatinine/eGFR annually for every person with diabetes.
• Type 1 diabetes: screening from 5 years after diagnosis.
• Type 2 diabetes: screening from diagnosis.

What slows or prevents it

• Blood pressure control — target usually under 130/80. ACE inhibitor or ARB class is first-line and proven to slow kidney disease.
• Blood sugar control — HbA1c targeted individually (usually 6.5–7%).
• SGLT2 inhibitors — a major recent advance; proven to reduce kidney failure, heart failure, and death in diabetic kidney disease.
• GLP-1 receptor agonist class — weight loss + heart and probably kidney benefit in diabetes.
• Non-steroidal mineralocorticoid-receptor antagonist class — newer option for proteinuric diabetic kidney disease.
• Low-salt diet (< 5 g/day), stop smoking, moderate alcohol.
• Avoid long-term NSAIDs and unregulated herbal products — both are major contributors to diabetic kidney injury in India.
• Manage cholesterol — statin class is usually recommended.

When to see a nephrologist

• eGFR falling below 60.
• Urine albumin rising despite ACE/ARB + SGLT2.
• Uncontrolled BP on three drugs.
• Unusual pattern (sudden onset, massive proteinuria, blood in urine) — may not be diabetic disease alone.
• Any stage with complications — anaemia, bone disease, acidosis, hyperkalaemia.